title: Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic.
abstract: The pentameric B subunit of verotoxin (VT) mediates the attachment to cell surface globotriaosyl ceramide (Gb3) to facilitate receptor-mediated endocytosis of the toxin. In highly toxin-sensitive tumor cells, the holotoxin and VT1 B subunit is targeted intracellularly to elements of the endoplasmic reticulum (ER)/nuclear membrane. In less sensitive cells, the toxin is targeted to components of the Golgi apparatus. We have studied two cell systems: the induced VT hypersensitivity of human astrocytoma cell lines cultured in the presence of sodium butyrate (compared to sodium propionate and capronate) and the increased VT sensitivity of multiple drug-resistant mutants as compared to parental human ovarian carcinoma cells. In both cases, a difference in the intracellular retrograde transport of the receptor-bound internalized toxin to the ER/nuclear envelope, as opposed to the Golgi, correlated with a >1,000-fold increase in cell sensitivity to VT. This change in intracellular routing may be due to sorting of Gb3 fatty acid isoforms, since nuclear targeting was found in turn to correlate with the preferential synthesis of Gb3 containing shorter chain (primarily C16) fatty acid species. We propose that the isoform-dependent traffic of Gb3 from the cell surface to the ER/nuclear membrane provides a new signal transduction pathway for Gb3 binding proteins.
authors: Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
authors: S
authors: S
authors: Arab
authors: C A
authors: CA
authors: Lingwood
mesh_terms: D001254:Astrocytoma / Q000473:pathology; D001427:Bacterial Toxins / Q000737:chemistry / Q000494:pharmacology*; D001692:Biological Transport; D001932:Brain Neoplasms / Q000473:pathology; D002087:Butyrates / Q000494:pharmacology; D002277:Carcinoma / Q000473:pathology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004705:Endocytosis / Q000502:physiology*; D004721:Endoplasmic Reticulum / Q000378:metabolism*; D005260:Female; D006017:Glycolipids / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008563:Membrane Lipids / Q000737:chemistry / Q000378:metabolism*; D015394:Molecular Structure; D009685:Nuclear Envelope / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D022622:Shiga Toxin 1; D015398:Signal Transduction / Q000502:physiology*; D013107:Sphingolipids / Q000737:chemistry / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D001427:Bacterial Toxins; D002087:Butyrates; D006017:Glycolipids; D008563:Membrane Lipids; D011993:Recombinant Fusion Proteins; D022622:Shiga Toxin 1; D013107:Sphingolipids; C063288:globotriaosyl lysosphingolipid